BPMC News and Press, Blueprint Medicines Corporation From 03/08/20

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen&#...

CAMBRIDGE, Mass. , Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that updated data from the Phase 2 PIONEER trial of avapri...

CAMBRIDGE, Mass. , Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in fireside chats at the follow...

Penny stocks might seem like a good investment because you can purchase many shares for a relatively small amount of money. But most of them represent businesses with questionable prospects at best, and owning thousands of shares of a worthless venture means your hard-earned money could vaporize...

Image source: The Motley Fool. Blueprint Medicines   (NASDAQ: BPMC) Q4 2019 Earnings Call Feb 13, 2020 , 8:30 a.m. ET Operator Continue reading

Blueprint Medicines Corporation (BPMC) Q4 2019 Results Earnings Conference Call February 13, 2020, 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Dr. Andy Boral - Chief Medical Officer Christy Rossi - Ch...

Blueprint Medicines  (NASDAQ: BPMC ): Q4 GAAP EPS of -$1.35 beats by $0.41 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quart...

Blueprint's (Most Recent) Raise Closed: TBD (proposed pricing on 1/22/20) Pricing: $69.00/share Amount: ~$325 million Over-allotment: TBD Blueprint Medicines ( BPMC ) recently announced a dilutive raise, sending share prices below key moving averages: Blueprint's la...

CAMBRIDGE, Mass. , Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m...